Research reviewThe Role of Vascular Endothelial Growth Factor in Wound Healing
Introduction
The term “chronic wound” describes a wound that occurs in a patient who has physiological impairments to healing (Table 1). These pathophysiologic processes predispose cutaneous wounds to deviate from the characteristics of acute wound healing. Although a chronic wound is not always slow to heal, it should be considered “emergent” in that it is often a nonhealing wound. An estimated 3 to 6 million chronic skin ulcers occur in patients every year in the United States. The most common underlying conditions are venous reflux, pressure, and diabetes mellitus [1, 2, 3, 4, 5].
In the vast majority of surgical procedures, nearly all acute wounds heal in an orderly and timely process [6], with a strength and integrity similar to normal skin [7, 8]. Wounds refractory to moist healing, however, may be candidates for growth factor therapy, which is assumed to stimulate missing or dysfunctional components of the chronic wound [9, 10, 11]. An angiogenic growth factor may promote closure of chronic wounds exhibiting hypoxia and compromised vascularity.
Vascular endothelial growth factor (VEGF) is one such candidate. It functions as an endothelial cell mitogen [12, 13, 14, 15, 16, 17], chemotactic agent [18, 19], and inducer of vascular permeability [20, 21, 22, 23, 24, 25, 26]. Other angiogenic growth factors such as basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGF-β) have been described, but VEGF is unique for its effects on multiple components of the wound-healing cascade, including angiogenesis and recently shown epithelialization and collagen deposition [27]. Purified growth factors [28] and cultured human cells [29, 30, 31] have both been approved by the Food and Drug Administration to accelerate closure of nonhealing wounds. This has transformed the field of wound healing by establishing the efficacy of a topical growth factor and cell therapy. Since angiogenesis maintains a critical role in wound healing, in the future, VEGF (alone or in combination therapy) may be used on patients with nonhealing wounds. This article reviews the role of angiogenesis and other mechanisms of VEGF in wound healing.
Section snippets
Structure and Heterogeneity
VEGF is a homodimeric glycoprotein that shares almost 20% amino acid homology with platelet-derived growth factor (PDGF) [16]. VEGF exists in 5 isoforms resulting from alternative splicing of its mRNA, with chain lengths of 121, 145, 165, 189, and 206 amino acids [32, 33, 34, 35]. These 5 forms are commonly referred to as VEGF-A (VEGF165), VEGF-B, VEGF-D, and placental growth factor. In addition, VEGF-C has been shown to be secreted by macrophages and their role in wound healing has begun to be
Cells in a Healing Wound Synthesize VEGF
VEGF is produced by many cell types that participate in wound healing: endothelial cells [37, 38], fibroblasts [39], smooth muscle cells [40, 41], platelets [42], neutrophils [43], and macrophages [44]. The dominant isoform of VEGF is the shorter variant, which is soluble in the extracellular space.
VEGF Receptors
In humans, VEGF binds with receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2), both high affinity receptors [45, 46, 47]. They are members of the Type 3 tyrosine kinase family, consisting of 7
VEGF Stimulates Multiple Components of the Angiogenic Cascade
One of VEGF's roles in wound healing is stimulation of angiogenesis. Wound-healing angiogenesis involves multiple steps including vasodilation, basement membrane degradation, endothelial cell migration, and endothelial cell proliferation [64]. Subsequently, capillary tube formation occurs, followed by anastomosis of parallel capillary sprouts (loop formation), and finally, new basement membrane formation. VEGF plays a role in several of these processes (Fig. 1).
Clinical Use of VEGF in Humans
Phase I clinical trials have been initiated for patients with nonspecific limb ischemia [118, 119], Buerger's disease [120], and myocardial ischemia [121]. As early as 1996, balloon transfer of plasmid DNA expressing VEGF165 was attempted on a nondiabetic patient with arterial occlusive disease in the lower extremity [118]. Following gene transfer to the distal popliteal artery, collateral vessels and flow to the leg were increased, and the site of transfer did not show intimal thickening.
Conclusions
VEGF stimulates wound healing via multiple mechanisms including collagen deposition, angiogenesis, and epithelialization. In the clinical setting, the mitogenic, chemotactic, and permeability effects of VEGF may potentially aid in promoting repair in nonhealing wounds in arterial occlusive disease and diabetes. It may also alleviate the “wound” of ischemic heart disease. By promoting angiogenesis, VEGF improves tissue perfusion. Sustained release of VEGF (through adenovirus gene, biodegradable
Acknowledgment
This work received financial support through National Institutes of Health Grant 5K08DK059424.
References (150)
- et al.
Pathophysiology of acute wound healing
Clin Dermatol
(2007) - et al.
Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
Biochem Biophys Res Commun
(1989) - et al.
The human gene for vascular endothelial growth factorMultiple protein forms are encoded through alternative exon splicing
J Biol Chem
(1991) - et al.
Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
J Biol Chem
(1992) - et al.
VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix
J Biol Chem
(1997) - et al.
Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing
Am J Pathol
(2007) - et al.
Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells
J Biol Chem
(1995) - et al.
Intracellular pool of vascular endothelial growth factor in human neutrophils
Blood
(1997) Vascular endothelial growth factor, a potent and selective angiogenic agent
J Biol Chem
(1996)- et al.
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
Biochem Biophys Res Commun
(1992)